Latest Japan News

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

The Koala Company posted a $24.6 million profit for FY26 on $332.3 million revenue, surpassing IPO forecasts with strong international growth and margin gains.

PolyNovo reported a 16.1% rise in FY26 revenue to AUD 150 million, driven by strong global sales and manufacturing expansion, yet net profit fell 44% due to a significant asset write-off from an R&D centre fire and lower tax benefits.

Dalrymple Bay Infrastructure reported a 14.2% rise in net profit for H1 2026, underpinned by higher terminal charges and ongoing capital investment, while raising distribution guidance by 8.5%.

1414 Degrees has inked a letter of intent with South Korea’s JR Energy Solution to jointly develop and scale battery cells using its SiNTL silicon anode technology, targeting defence, UAV, space, and robotics markets.

Comms Group Limited reported record FY26 revenue and EBITDA growth, driven by organic expansion and TasmaNet acquisition, while progressing the $30m sale of its ICT business to streamline operations and support shareholder returns.

Eagle Mountain Mining has kicked off a 6,000-metre drilling program at its Oracle Ridge copper project in Arizona, funded and operated by JV partner Nittetsu Mining. The campaign aims to expand known mineralisation and explore new targets identified by recent geophysical surveys.

Guzman y Gomez (ASX: GYG) reported strong FY26 growth with network sales rising 18% and underlying NPAT up 30%, while completing its exit from the US market and announcing a 48 cents fully franked dividend.

AnteoTech has formalised a strategic alliance with South Korea’s Xerabrid to co-develop and commercialise a breakthrough battery separator combining their proprietary technologies, targeting high-performance applications in eVTOL, EVs, and consumer electronics.

Dimerix has received a US$10 million upfront payment from Everest Medicines under a regional licensing deal for DMX-200 targeting FSGS in Greater China, South Korea and Southeast Asia. This deal marks Dimerix’s fifth commercial partnership for DMX-200, collectively worth up to A$1.9 billion in milestones and royalties.

Telix Pharmaceuticals returned to profit in H1 2026, driven by strong U.S. sales of Illuccix and Gozellix, a $40 million upfront from Regeneron collaboration, and expanded R&D investment.

Whitehaven Coal reported a 29% drop in underlying net profit to $227 million for FY26, despite record safety outcomes and successful debt refinancing that lowered funding costs and extended maturities.